Trial Outcomes & Findings for The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery (NCT NCT00413244)
NCT ID: NCT00413244
Last Updated: 2017-01-05
Results Overview
Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.
COMPLETED
PHASE3
51 participants
at 6 months
2017-01-05
Participant Flow
Subjects recruited for the study were male patients with stable cardiac status at least 3 months after Percutaneous Coronary Intervention (PCI) at the Cardiac Catheterization Lab of Mount Sinai Hospital from July 2007 to August 2013.
Participant milestones
| Measure |
Androgel
Androgel 5 grams
|
Placebo
Matching Placebo
|
|---|---|---|
|
Overall Study
STARTED
|
31
|
20
|
|
Overall Study
COMPLETED
|
21
|
19
|
|
Overall Study
NOT COMPLETED
|
10
|
1
|
Reasons for withdrawal
| Measure |
Androgel
Androgel 5 grams
|
Placebo
Matching Placebo
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
10
|
1
|
Baseline Characteristics
The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery
Baseline characteristics by cohort
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
Total
n=51 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
58.3 years
STANDARD_DEVIATION 8.2 • n=99 Participants
|
58.9 years
STANDARD_DEVIATION 7.3 • n=107 Participants
|
58.5 years
STANDARD_DEVIATION 7.81 • n=206 Participants
|
|
Gender
Female
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Gender
Male
|
31 Participants
n=99 Participants
|
20 Participants
n=107 Participants
|
51 Participants
n=206 Participants
|
|
Hypertension
Yes
|
30 participants
n=99 Participants
|
16 participants
n=107 Participants
|
46 participants
n=206 Participants
|
|
Hypertension
No
|
1 participants
n=99 Participants
|
4 participants
n=107 Participants
|
5 participants
n=206 Participants
|
|
Body Mass Index
|
30.8 kg/m^2
STANDARD_DEVIATION 5.8 • n=99 Participants
|
28.0 kg/m^2
STANDARD_DEVIATION 4.3 • n=107 Participants
|
29.7 kg/m^2
STANDARD_DEVIATION 5.4 • n=206 Participants
|
|
Diabetes
Yes
|
16 participants
n=99 Participants
|
6 participants
n=107 Participants
|
22 participants
n=206 Participants
|
|
Diabetes
No
|
15 participants
n=99 Participants
|
14 participants
n=107 Participants
|
29 participants
n=206 Participants
|
|
Total Testosterone
|
246.7 ng/dL
STANDARD_DEVIATION 63.5 • n=99 Participants
|
263.7 ng/dL
STANDARD_DEVIATION 71.9 • n=107 Participants
|
253.36 ng/dL
STANDARD_DEVIATION 66.8 • n=206 Participants
|
|
Systolic Blood Pressure
|
123.81 mmHg
STANDARD_DEVIATION 13.81 • n=99 Participants
|
128.05 mmHg
STANDARD_DEVIATION 20.84 • n=107 Participants
|
125.47 mmHg
STANDARD_DEVIATION 16.85 • n=206 Participants
|
|
Diastolic Blood Pressure
|
76.32 mmHg
STANDARD_DEVIATION 9.03 • n=99 Participants
|
75.10 mmHg
STANDARD_DEVIATION 11.65 • n=107 Participants
|
75.84 mmHg
STANDARD_DEVIATION 10.04 • n=206 Participants
|
|
Hematocrit
|
40.69 percent of cells
STANDARD_DEVIATION 3.00 • n=99 Participants
|
40.93 percent of cells
STANDARD_DEVIATION 3.18 • n=107 Participants
|
40.78 percent of cells
STANDARD_DEVIATION 3.04 • n=206 Participants
|
|
White Blood Cell Count
|
6.25 cells x10^3/uL
STANDARD_DEVIATION 1.78 • n=99 Participants
|
6.49 cells x10^3/uL
STANDARD_DEVIATION 1.63 • n=107 Participants
|
6.34 cells x10^3/uL
STANDARD_DEVIATION 1.71 • n=206 Participants
|
|
Red Blood Cell Count
|
4.58 cells x10^6/uL
STANDARD_DEVIATION 0.44 • n=99 Participants
|
4.67 cells x10^6/uL
STANDARD_DEVIATION 0.42 • n=107 Participants
|
4.62 cells x10^6/uL
STANDARD_DEVIATION 0.43 • n=206 Participants
|
|
Aging male syndrome questionnaire
|
36.48 units on a scale
STANDARD_DEVIATION 11.36 • n=99 Participants
|
35.85 units on a scale
STANDARD_DEVIATION 10.24 • n=107 Participants
|
36.24 units on a scale
STANDARD_DEVIATION 10.83 • n=206 Participants
|
|
Exercise Time
|
507.29 seconds
STANDARD_DEVIATION 153.48 • n=99 Participants
|
530.00 seconds
STANDARD_DEVIATION 120.08 • n=107 Participants
|
516.20 seconds
STANDARD_DEVIATION 104.49 • n=206 Participants
|
|
International Prostate Symptom Score (IPSS)
|
5.68 units on a scale
STANDARD_DEVIATION 4.77 • n=99 Participants
|
4.55 units on a scale
STANDARD_DEVIATION 4.7 • n=107 Participants
|
5.24 units on a scale
STANDARD_DEVIATION 4.73 • n=206 Participants
|
|
Metabolic equivalent of task (METs)
|
10.03 MET units
STANDARD_DEVIATION 2.58 • n=99 Participants
|
10.05 MET units
STANDARD_DEVIATION 1.99 • n=107 Participants
|
10.04 MET units
STANDARD_DEVIATION 2.34 • n=206 Participants
|
|
Reactive hyperemia index (RHI)
|
1.97 ml
STANDARD_DEVIATION 0.72 • n=99 Participants
|
1.85 ml
STANDARD_DEVIATION 0.54 • n=107 Participants
|
1.92 ml
STANDARD_DEVIATION 0.66 • n=206 Participants
|
|
Total Cholesterol
|
157.29 mg/dL
STANDARD_DEVIATION 47.10 • n=99 Participants
|
144.45 mg/dL
STANDARD_DEVIATION 28.85 • n=107 Participants
|
152.25 mg/dL
STANDARD_DEVIATION 41.08 • n=206 Participants
|
|
LDL
|
86.48 mg/dL
STANDARD_DEVIATION 40.52 • n=99 Participants
|
80.90 mg/dL
STANDARD_DEVIATION 26.77 • n=107 Participants
|
84.29 mg/dL
STANDARD_DEVIATION 35.57 • n=206 Participants
|
|
Triglycerides
|
142.23 mg/dL
STANDARD_DEVIATION 100.95 • n=99 Participants
|
109.90 mg/dL
STANDARD_DEVIATION 50.86 • n=107 Participants
|
129.55 mg/dL
STANDARD_DEVIATION 85.74 • n=206 Participants
|
|
Waist Circumference
|
42.66 inches
STANDARD_DEVIATION 5.21 • n=99 Participants
|
41.31 inches
STANDARD_DEVIATION 4.65 • n=107 Participants
|
42.13 inches
STANDARD_DEVIATION 4.99 • n=206 Participants
|
|
Weight
|
205.73 lbs
STANDARD_DEVIATION 39.22 • n=99 Participants
|
194.50 lbs
STANDARD_DEVIATION 36.62 • n=107 Participants
|
201.32 lbs
STANDARD_DEVIATION 38.25 • n=206 Participants
|
PRIMARY outcome
Timeframe: at 6 monthsPopulation: Subjects analyzed were only those subjects with ST depression at baseline
Treadmill exercise testing performed according to the Bruce protocol (MAX-1 Marquette advanced exercise system, software version 002E). The system analyzed the signal averaged ECG and produces a graphical display of the level of the ST segment 80 ms after the J point against time. Time to 1 mm ST depression was measured from computer derived analysis, effectively eliminating observer bias.
Outcome measures
| Measure |
Androgel
n=10 Participants
Androgel 5 grams
|
Placebo
n=11 Participants
Matching Placebo
|
|---|---|---|
|
Cardiac Stress Test: Time to ST Depression
at 1 month
|
439.1 seconds
Standard Deviation 205.2
|
279.5 seconds
Standard Deviation 130.0
|
|
Cardiac Stress Test: Time to ST Depression
at 3 months
|
364.0 seconds
Standard Deviation 141.4
|
292.6 seconds
Standard Deviation 63.5
|
|
Cardiac Stress Test: Time to ST Depression
at 6 months
|
433.0 seconds
Standard Deviation 123.2
|
342.2 seconds
Standard Deviation 62.7
|
PRIMARY outcome
Timeframe: At 1 month, 3 months, and 6 monthsPopulation: Subjects analyzed were only those subjects with ST depression at baseline
Exercise capacity was measured using exercise time.
Outcome measures
| Measure |
Androgel
n=10 Participants
Androgel 5 grams
|
Placebo
n=11 Participants
Matching Placebo
|
|---|---|---|
|
Cardiac Stress Testing: Exercise Capacity
at 6 months
|
614.0 seconds
Standard Deviation 115.4
|
470.0 seconds
Standard Deviation 143.8
|
|
Cardiac Stress Testing: Exercise Capacity
at 1 month
|
589.7 seconds
Standard Deviation 114.6
|
452.4 seconds
Standard Deviation 122.7
|
|
Cardiac Stress Testing: Exercise Capacity
at 3 months
|
607.6 seconds
Standard Deviation 152.0
|
472.1 seconds
Standard Deviation 98.6
|
SECONDARY outcome
Timeframe: up to 6 monthsA cardiac disease-related quality-of-life measure. The SAQ is a self-report instrument with 19 items that, yields five subscale scores: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important. Data not collected.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 6 monthsPopulation: Subjects analyzed were only those subjects with ST depression at baseline
The Reactive Hyperemia Index measures the endothelial function and predicts future coronary events. In general RHI values below 2 are categorized as endothelial dysfunction and have a greater plaque burden, whereas higher RHI values are considered normal or improved endothelial function. PAT is the technique to non-invasively assess endothelial function. It comprises finger probes to evaluate digital volume changes.
Outcome measures
| Measure |
Androgel
n=10 Participants
Androgel 5 grams
|
Placebo
n=11 Participants
Matching Placebo
|
|---|---|---|
|
Reactive Hyperemia Index
At baseline
|
1.96 mls
Standard Deviation 0.72
|
1.85 mls
Standard Deviation 0.54
|
|
Reactive Hyperemia Index
at 1 month
|
1.85 mls
Standard Deviation 0.49
|
1.81 mls
Standard Deviation 0.52
|
|
Reactive Hyperemia Index
at 3 months
|
1.70 mls
Standard Deviation 0.49
|
1.77 mls
Standard Deviation 0.37
|
|
Reactive Hyperemia Index
at 6 moths
|
1.83 mls
Standard Deviation 0.58
|
1.74 mls
Standard Deviation 0.53
|
SECONDARY outcome
Timeframe: 6 monthsIPSS has 7 questions related to symptoms, each item scored 1-5. Total score can range from 0 to 35 (asymptomatic to very symptomatic). The 8th question refers to the patient's perceived quality of life ranged from 0 to 6 ("delighted" to "terrible".) Data not collected.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 6 monthsPopulation: Subjects analyzed were only those subjects with ST depression at baseline
The Metabolic Equivalent of Task (MET), or simply metabolic equivalent, is a physiological measure expressing the energy cost of physical activities and is defined as the ratio of metabolic rate (and therefore the rate of energy consumption) during a specific physical activity to a reference metabolic rate, set by convention to 3.5 ml O2·kg-1·min-1 or equivalently
Outcome measures
| Measure |
Androgel
n=10 Participants
Androgel 5 grams
|
Placebo
n=11 Participants
Matching Placebo
|
|---|---|---|
|
Metabolic Equivalents of Task (METS)
at baseline
|
11.0 METS units
Standard Deviation 2.2
|
9.0 METS units
Standard Deviation 1.3
|
|
Metabolic Equivalents of Task (METS)
at 1 month
|
11.4 METS units
Standard Deviation 2.2
|
9.0 METS units
Standard Deviation 1.9
|
|
Metabolic Equivalents of Task (METS)
at 3 months
|
11.9 METS units
Standard Deviation 3.0
|
9.2 METS units
Standard Deviation 1.5
|
|
Metabolic Equivalents of Task (METS)
at 6 months
|
12.2 METS units
Standard Deviation 2.2
|
9.4 METS units
Standard Deviation 2.3
|
SECONDARY outcome
Timeframe: At baseline, 1 month, 3 months, and 6 monthsThe scale assesses symptoms of aging and their impact on HRQoL in males, and increases with increasing severity (1 to 5) of subjectively perceived complaints in 17 items. Scale ranges from 17-85 (no symptoms to extremely severe symptoms.)
Outcome measures
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
|---|---|---|
|
Aging Male Symptoms (AMS)
Baseline
|
36.5 units on a scale
Standard Deviation 11.4
|
35.8 units on a scale
Standard Deviation 10.2
|
|
Aging Male Symptoms (AMS)
At 1 month
|
32.9 units on a scale
Standard Deviation 10.1
|
29.8 units on a scale
Standard Deviation 11.6
|
|
Aging Male Symptoms (AMS)
At 3 months
|
36.5 units on a scale
Standard Deviation 11.4
|
35.9 units on a scale
Standard Deviation 10.2
|
|
Aging Male Symptoms (AMS)
At 6 months
|
31.2 units on a scale
Standard Deviation 8.5
|
31.4 units on a scale
Standard Deviation 9.8
|
SECONDARY outcome
Timeframe: At baseline, 1 month, 3 months, and 6 monthsQuestions 1-5 15 of the IIEF relates to erectile function scale 0 - 30 (severe erectile dysfunction to no erectile dysfunction).
Outcome measures
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
|---|---|---|
|
International Index of Erectile Function (IIEF)
at baseline
|
12.4 units on a scale
Standard Deviation 8.7
|
12.2 units on a scale
Standard Deviation 9.4
|
|
International Index of Erectile Function (IIEF)
at 1 month
|
14.1 units on a scale
Standard Deviation 9.0
|
10.1 units on a scale
Standard Deviation 9.2
|
|
International Index of Erectile Function (IIEF)
at 3 months
|
15.7 units on a scale
Standard Deviation 9.6
|
14.2 units on a scale
Standard Deviation 10.8
|
|
International Index of Erectile Function (IIEF)
at 6 months
|
15.0 units on a scale
Standard Deviation 10.0
|
12.5 units on a scale
Standard Deviation 9.7
|
SECONDARY outcome
Timeframe: At baseline, 1 month, 3 months, and 6 monthsQuestions 9-10 of the IIEF relates to orgasmic function scale 0 - 10 (from no impairment to severe impairment)
Outcome measures
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
|---|---|---|
|
IIEF-II Orgasmic Function
at baseline
|
4.8 units on a scale
Standard Deviation 3.3
|
4.4 units on a scale
Standard Deviation 3.6
|
|
IIEF-II Orgasmic Function
at 1 month
|
5.9 units on a scale
Standard Deviation 3.5
|
4.2 units on a scale
Standard Deviation 4.2
|
|
IIEF-II Orgasmic Function
at 3 months
|
5.7 units on a scale
Standard Deviation 3.7
|
5.8 units on a scale
Standard Deviation 4.2
|
|
IIEF-II Orgasmic Function
at 6 months
|
6.1 units on a scale
Standard Deviation 3.4
|
5.5 units on a scale
Standard Deviation 4.3
|
SECONDARY outcome
Timeframe: At baseline, 1 month, 3 months, and 6 monthsQuestions 11-12 of the IIEF relates to sexual desire scale 0-10 (from very low to very high)
Outcome measures
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
|---|---|---|
|
IIEF -III: Sexual Desire
at 6 months
|
6.6 units on a scale
Standard Deviation 2.4
|
5.5 units on a scale
Standard Deviation 2.6
|
|
IIEF -III: Sexual Desire
at baseline
|
5.0 units on a scale
Standard Deviation 2.1
|
5.4 units on a scale
Standard Deviation 1.8
|
|
IIEF -III: Sexual Desire
at 1 month
|
5.6 units on a scale
Standard Deviation 2.7
|
4.8 units on a scale
Standard Deviation 2.4
|
|
IIEF -III: Sexual Desire
at 3 months
|
6.3 units on a scale
Standard Deviation 2.3
|
5.6 units on a scale
Standard Deviation 2.0
|
SECONDARY outcome
Timeframe: At baseline, 1 month, 3 months, and 6 monthsQuestions 6,7, 8 of the IIEF relates to intercourse satisfaction scale 0 - 15 (from very dissatisfied to very satisfied)
Outcome measures
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
|---|---|---|
|
IIEF-IV: Intercourse Satisfaction
at baseline
|
5.5 units on a scale
Standard Deviation 4.0
|
5.0 units on a scale
Standard Deviation 4.6
|
|
IIEF-IV: Intercourse Satisfaction
at 1 month
|
6.2 units on a scale
Standard Deviation 4.6
|
3.6 units on a scale
Standard Deviation 4.4
|
|
IIEF-IV: Intercourse Satisfaction
at 3 months
|
6.8 units on a scale
Standard Deviation 4.9
|
6.0 units on a scale
Standard Deviation 5.1
|
|
IIEF-IV: Intercourse Satisfaction
at 6 months
|
6.9 units on a scale
Standard Deviation 5.1
|
5.2 units on a scale
Standard Deviation 5.1
|
SECONDARY outcome
Timeframe: At baseline, 1 month, 3 months, and 6 monthsQuestions 13,14 of the IIEF relates to specifically to overall satisfaction scale from 0 - 10 (very dissatisfied to very satisfied)
Outcome measures
| Measure |
Androgel
n=31 Participants
Androgel 5 grams
|
Placebo
n=20 Participants
Matching Placebo
|
|---|---|---|
|
IIEF-V: Over-all Satisfaction
at 3 months
|
5.2 units on a scale
Standard Deviation 2.9
|
5.2 units on a scale
Standard Deviation 3.0
|
|
IIEF-V: Over-all Satisfaction
at 6 months
|
6.0 units on a scale
Standard Deviation 3.0
|
4.9 units on a scale
Standard Deviation 3.2
|
|
IIEF-V: Over-all Satisfaction
at baseline
|
4.8 units on a scale
Standard Deviation 2.5
|
4.3 units on a scale
Standard Deviation 2.4
|
|
IIEF-V: Over-all Satisfaction
at 1 month
|
4.9 units on a scale
Standard Deviation 2.9
|
3.8 units on a scale
Standard Deviation 2.7
|
Adverse Events
Androgel
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Mary Ann McLaughlin
Icahn School of Medicine at Mount Sinai
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place